BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27

• Press Releases

  PharmaResearch Receives U.S. FDA Clearance to Initiate Phase 1 Clinical Trial of Nano Anticancer Drug, PRD-101

  February 6, 2026

   · 

  2 min read
• Press Releases

  HUTCHMED to Announce 2025 Final Results

  February 6, 2026

   · 

  1 min read
• Press Releases

  Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer

  February 6, 2026

   · 

  6 min read
• Press Releases

  Invitation to the Presentation of Cantargia’s Annual Results for 2025

  February 6, 2026

   · 

  1 min read
• 

  GLP-1

  Makary Blasts ‘Illegal Copycat Drugs’ as Hims Launches Compounded Wegovy Pill

  Novo Nordisk has also spoken out strongly against Hims & Hers’ compounded Wegovy pill, with CEO Maziar Mike Doustdar telling investors the knockoff version is a waste of money.

  February 6, 2026

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Immunology and inflammation

  Priovant Plots Path to Phase 3 as Brepocitinib Clears Mid-Stage Skin Disease Study

  According to Priovant, the Phase 2 BEACON study is the first industry-sponsored placebo-controlled trial in cutaneous sarcoidosis to deliver positive data.

  February 6, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  iSpecimen Achieves Rapid Procurement Milestone for Influenza Research

  February 6, 2026

   · 

  3 min read
• Press Releases

  iSpecimen Announces Milestone 2: System Integration and Marketplace Activation Complete

  Live Production Marketplace Now Available

  February 6, 2026

   · 

  5 min read
• 

  Earnings

  Biogen’s ‘Bridge To Growth’ Cuts Through a Stacked Phase 3 Pipeline

  With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage pipeline and hunting for deals to build its return to growth.

  February 6, 2026

   · 

  2 min read

   · 

  Annalee Armstrong
• Press Releases

  TempraMed Launches National Brick and Mortar Pharmacy Roll Out, Shipping Products to Maccabi Pharmacies Across Israel

  Key Commercialization Milestone in Retail Pharmacy Network that Serves Over 2.8 Million Insured Members

  February 6, 2026

   · 

  5 min read